Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.75 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16037216 | 1.00 | P2RX7 (0.75) | P2RX7CYP2C8CYP2C19 | |
| SCHEMBL16037214 | 1.00 | P2RX7 (0.75) | P2RX7CYP2C8CYP2C19 | |
| SCHEMBL16037292 | 0.91 | P2RX7 (0.75) | P2RX7CYP2C8CYP2C19 | |
| SCHEMBL16037288 | 0.91 | P2RX7 (0.75) | P2RX7CYP2C8CYP2C19 | |
| Jnj-54175446 SCHEMBL16036477 | 0.86 | P2RX7 (1.00) | P2RX7CYP2C8CYP2C19 | |
| Jnj-54175446 SCHEMBL31347774 | 0.86 | P2RX7 (1.00) | P2RX7CYP2C8CYP2C19 | |
| Jnj-54175446 SCHEMBL16036476 | 0.86 | P2RX7 (1.00) | P2RX7CYP2C8CYP2C19 | |
| Jnj-54175446 SCHEMBL30900468 | 0.86 | P2RX7 (1.00) | P2RX7CYP2C8CYP2C19 | |
| Jnj-54175446 SCHEMBL16036794 | 0.86 | P2RX7 (1.00) | P2RX7CYP2C8CYP2C19 | |
| SCHEMBL16127738 | 0.86 | P2RX7 (1.00) | P2RX7CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | claimed |
| EP-3495365-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | claimed |
| US-10112937-B2 | P2X7 modulators and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-30 | — | — | US | claimed |
| EP-2970267-B3 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-30 | — | — | EP | claimed |
| EP-2970267-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-24 | — | — | EP | claimed |
| US-20160376271-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV | 2016-12-29 | — | — | US | claimed |
| US-20160039809-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | claimed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | claimed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | claimed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014152604-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | P2RX7 2/4885CYP2C8 1097/4885CYP2C19 704/4885 |
| US-20160376271-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | P2RX7 2/4885CYP2C8 1097/4885CYP2C19 704/4885 |
| US-10112937-B2 | P2X7 modulators and methods of use | P2RX2, P2RX7, P2RX5 | P2RX7 2/4885CYP2C8 967/4885CYP2C19 530/4885 |
| US-20160039809-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RX5 | P2RX7 2/4885CYP2C8 1040/4885CYP2C19 587/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | P2RX7 2/4885CYP2C8 1097/4885CYP2C19 704/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | P2RX7 2/4885CYP2C8 1097/4885CYP2C19 704/4885 |
| US-20140275015-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | P2RX7 2/4885CYP2C8 1097/4885CYP2C19 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.